Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13705145 | 0.94 | ABHD6 (0.42) | ABHD6DAGLADPP4NR1H2NR1H3 | |
| SCHEMBL4287711 | 0.93 | HCRTR1 (0.33) | ABHD6DAGLA | |
| SCHEMBL4287706 | 0.93 | HCRTR1 (0.33) | ABHD6DAGLA | |
| SCHEMBL4287715 | 0.93 | HCRTR1 (0.33) | ABHD6DAGLA | |
| SCHEMBL13705252 | 0.89 | ABHD6 (0.41) | ABHD6DAGLADPP4NR1H2NR1H3 | |
| SCHEMBL13705228 | 0.88 | ABHD6 (0.41) | ABHD6DAGLADPP4NR1H2NR1H3 | |
| SCHEMBL13705169 | 0.88 | ABHD6 (0.43) | ABHD6DAGLADPP4NR1H2NR1H3 | |
| SCHEMBL4286201 | 0.88 | ABHD6 (0.43) | ABHD6DAGLADPP4NR1H2NR1H3 | |
| SCHEMBL13705233 | 0.88 | ABHD6 (0.43) | ABHD6DAGLADPP4NR1H2NR1H3 | |
| SCHEMBL13705236 | 0.86 | ABHD6 (0.43) | ABHD6DAGLADPP4NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ABHD6 3736/4885DAGLA 4309/4885DPP4 113/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ABHD6 3736/4885DAGLA 4309/4885DPP4 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.